 Jefferson Parish

Retina Associates New Orleans

Macular Degeneration

Geographic Atrophy

Atrophy

ABP 938

EYP-1901

APL-2

Aflibercept

Eylea®

Amgen

Apellis Pharmaceuticals

EyePoint Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Retina Associates New Orleans | Jefferson Parish

Site insights

Work at this site?

Active trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Trial sponsors